Cerulean Pharma Cmn (CERU) 2.05 $CERU
Cerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
BusinessWire - Thu Jun 23, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the Phase 2a stage of an ongoing Phase 1/2a clinical trial of CRLX301 in patients with advanced solid tumors.
CERU: 2.05 (-0.09)
Cerulean Announces Publication in Cancer Research
BusinessWire - Wed Jun 22, 8:20AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of preclinical proof of concept data for its lead compound, CRLX101, in the journal Cancer Research. The publication highlights that CRLX101 demonstrated strong antitumor activity, as monotherapy and in combination with Avastin(R) (bevacizumab), leading to complete tumor regression, reduced metastasis, and extended survival of mice with metastatic disease. These preclinical results were derived from mouse models of orthotropic primary triple-negative breast tumor xenografts, including a patient-derived xenograft and a model of post-surgical, advanced metastatic breast cancer. The article was published online.
CERU: 2.05 (-0.09)
Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan L. Kelley, M.D. to the Company's Board of Directors.
IMDZ: 8.25 (-0.05), CERU: 2.05 (-0.09)
Cerulean Announces Manuscript Published in Annals of Oncology
BusinessWire - Thu Jun 09, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the manuscript of clinical data for its lead compound, CRLX101, in the journal Annals of Oncology. The manuscript highlights results from an open-label, single arm Phase 1b/2 investigator-sponsored trial (IST) of CRLX101 in combination with Avastin(R) (bevacizumab) in patients with metastatic renal cell carcinoma (RCC). The trial achieved its primary endpoint of establishing a recommended Phase 2 dose and showed preliminary anti-tumor activity. The article is available online. Results from the trial also were presented at the 2015 American Society of Clinical Oncology annual meeting on June 1, 2015 and at the 2015 International Kidney Cancer Symposium on November 4, 2015.
CERU: 2.05 (-0.09)
Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
BusinessWire - Thu May 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company will present in an oral session Phase 1b results of an ongoing clinical trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer at the Gynecologic Oncology 2016 Conference being held May 19-21 in San Antonio, Texas. This trial is being conducted by Cerulean in collaboration with the GOG Foundation, Inc.
CERU: 2.05 (-0.09)
Cerulean to Present at the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:12PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster presentation on CRLX301 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago.
CERU: 2.05 (-0.09)
Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA(TM)
BusinessWire - Tue May 10, 6:30AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA(TM) (olaparib) in patients with advanced solid tumors. This trial is being conducted by the National Cancer Institute (NCI), in collaboration with AstraZeneca and Cerulean. It is under the direction of NCI investigators, Anish Thomas, MBBS, M.D., Staff Clinician at the Thoracic and Gastrointestinal Oncology Branch of the Center for Cancer Research at the NCI, and Yves Pommier, M.D., Ph.D., an expert in DNA repair, and Chief of the Developmental Therapeutics Branch at the NCI.
CERU: 2.05 (-0.09)
Cerulean reports 1Q loss
Automated Insights - Mon May 02, 4:31PM CDT
WALTHAM, Mass. (AP) _ Cerulean Pharma Inc. (CERU) on Monday reported a loss of $13.5 million in its first quarter.
CERU: 2.05 (-0.09)
Cerulean Reports First Quarter 2016 Corporate Highlights and Financial Results
BusinessWire - Mon May 02, 3:06PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 2016.
CERU: 2.05 (-0.09)
Cerulean to Host First Quarter 2016 Conference Call on May 2
BusinessWire - Mon Apr 25, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2.
CERU: 2.05 (-0.09)
Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
BusinessWire - Tue Apr 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of clinical data in a late-breaker at the 2016 American Association for Cancer Research (AACR) Annual Meeting. Adrian Senderowicz, M.D., Senior Vice President and Chief Medical Officer of Cerulean will present results from the first 18 patients enrolled in an investigator-sponsored trial.
CERU: 2.05 (-0.09)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.05 (-0.09), VVUS: 1.10 (unch), PETX: 5.96 (-0.28), GALE: 2.03 (-0.12)
Cerulean to Present at 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 12:50 p.m. ET.
CERU: 2.05 (-0.09)
Cerulean Pharma (CERU) Jumps: Stock Moves 8.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:15AM CDT
Cerulean Pharma Inc (CERU) shares rose almost 9% in the last trading session.
CERU: 2.05 (-0.09), CALA: 4.01 (-0.20)
Nike and Newmont Mining fall; Pepco, Health Net rise
AP - Wed Mar 23, 3:55PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq stock market:
POM: 26.93 (+5.69), GILD: 80.54 (-2.83), NKE: 52.70 (-1.42), CERU: 2.05 (-0.09), FRED: 15.21 (-0.37), RHT: 73.80 (-4.59), NEM: 37.30 (+1.91), HNT: 67.19 (+2.38)
Top Penny Stocks On Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 12:24PM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. BBLU, LUNA, CERU, and SFOR have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
LUNA: 1.20 (unch), CERU: 2.05 (-0.09), BBLU: 0.04 (-0.01)
Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue
BusinessWire - Wed Mar 23, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of clinical data for its lead compound, CRLX101, in the journal Proceedings of the National Academy of Sciences (PNAS). The publication highlights results from an investigator-sponsored clinical trial, in which pre- and post- treatment tumor biopsies from patients with gastric cancer treated with CRLX101 show the presence of CRLX101 and its payload, camptothecin, in tumors, and their absence in surrounding normal tissue. Importantly, inhibition of the molecular targets of CRLX101 was demonstrated in post-treatment biopsies. The article was published online. Initial results from the trial were presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on November 7, 2015.
CERU: 2.05 (-0.09)
Cerulean Presents CRLX301 Phase 1 Data at the 14th International Congress on Targeted Anticancer Therapies
BusinessWire - Mon Mar 21, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of data from the Company's ongoing Phase 1/2a study of CRLX301 in patients with refractory solid tumors. CRLX301 is an NDC designed to concentrate in tumors and slowly release its payload, docetaxel, inside the cancer cells while sparing healthy tissue. The abstract, entitled "A phase 1 study of CRLX301, a novel Nanoparticle-Drug Conjugate (NDC) containing docetaxel, in patients with refractory solid tumors," will be presented during a poster session at the 14th International Congress on Targeted Anticancer Therapies being held March 21-23, 2016, in Washington, DC.
CERU: 2.05 (-0.09)
Cerulean Announces Data Presentations at the 2016 American Association for Cancer Research Annual Meeting
BusinessWire - Wed Mar 16, 3:37PM CDT
--Four Poster Presentations Featuring Preclinical and Clinical Data for CRLX101 and CRLX301
CERU: 2.05 (-0.09)
Cerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
BusinessWire - Thu Jun 23, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the Phase 2a stage of an ongoing Phase 1/2a clinical trial of CRLX301 in patients with advanced solid tumors.
CERU: 2.05 (-0.09)
Cerulean Announces Publication in Cancer Research
BusinessWire - Wed Jun 22, 8:20AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of preclinical proof of concept data for its lead compound, CRLX101, in the journal Cancer Research. The publication highlights that CRLX101 demonstrated strong antitumor activity, as monotherapy and in combination with Avastin(R) (bevacizumab), leading to complete tumor regression, reduced metastasis, and extended survival of mice with metastatic disease. These preclinical results were derived from mouse models of orthotropic primary triple-negative breast tumor xenografts, including a patient-derived xenograft and a model of post-surgical, advanced metastatic breast cancer. The article was published online.
CERU: 2.05 (-0.09)
Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan L. Kelley, M.D. to the Company's Board of Directors.
IMDZ: 8.25 (-0.05), CERU: 2.05 (-0.09)
Cerulean Announces Manuscript Published in Annals of Oncology
BusinessWire - Thu Jun 09, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the manuscript of clinical data for its lead compound, CRLX101, in the journal Annals of Oncology. The manuscript highlights results from an open-label, single arm Phase 1b/2 investigator-sponsored trial (IST) of CRLX101 in combination with Avastin(R) (bevacizumab) in patients with metastatic renal cell carcinoma (RCC). The trial achieved its primary endpoint of establishing a recommended Phase 2 dose and showed preliminary anti-tumor activity. The article is available online. Results from the trial also were presented at the 2015 American Society of Clinical Oncology annual meeting on June 1, 2015 and at the 2015 International Kidney Cancer Symposium on November 4, 2015.
CERU: 2.05 (-0.09)
Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
BusinessWire - Thu May 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company will present in an oral session Phase 1b results of an ongoing clinical trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer at the Gynecologic Oncology 2016 Conference being held May 19-21 in San Antonio, Texas. This trial is being conducted by Cerulean in collaboration with the GOG Foundation, Inc.
CERU: 2.05 (-0.09)
Cerulean to Present at the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:12PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster presentation on CRLX301 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago.
CERU: 2.05 (-0.09)
Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA(TM)
BusinessWire - Tue May 10, 6:30AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA(TM) (olaparib) in patients with advanced solid tumors. This trial is being conducted by the National Cancer Institute (NCI), in collaboration with AstraZeneca and Cerulean. It is under the direction of NCI investigators, Anish Thomas, MBBS, M.D., Staff Clinician at the Thoracic and Gastrointestinal Oncology Branch of the Center for Cancer Research at the NCI, and Yves Pommier, M.D., Ph.D., an expert in DNA repair, and Chief of the Developmental Therapeutics Branch at the NCI.
CERU: 2.05 (-0.09)
Cerulean reports 1Q loss
Automated Insights - Mon May 02, 4:31PM CDT
WALTHAM, Mass. (AP) _ Cerulean Pharma Inc. (CERU) on Monday reported a loss of $13.5 million in its first quarter.
CERU: 2.05 (-0.09)
Cerulean Reports First Quarter 2016 Corporate Highlights and Financial Results
BusinessWire - Mon May 02, 3:06PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 2016.
CERU: 2.05 (-0.09)
Cerulean to Host First Quarter 2016 Conference Call on May 2
BusinessWire - Mon Apr 25, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2.
CERU: 2.05 (-0.09)
Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
BusinessWire - Tue Apr 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of clinical data in a late-breaker at the 2016 American Association for Cancer Research (AACR) Annual Meeting. Adrian Senderowicz, M.D., Senior Vice President and Chief Medical Officer of Cerulean will present results from the first 18 patients enrolled in an investigator-sponsored trial.
CERU: 2.05 (-0.09)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.05 (-0.09), VVUS: 1.10 (unch), PETX: 5.96 (-0.28), GALE: 2.03 (-0.12)
Cerulean to Present at 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 12:50 p.m. ET.
CERU: 2.05 (-0.09)
Cerulean Pharma (CERU) Jumps: Stock Moves 8.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:15AM CDT
Cerulean Pharma Inc (CERU) shares rose almost 9% in the last trading session.
CERU: 2.05 (-0.09), CALA: 4.01 (-0.20)
Nike and Newmont Mining fall; Pepco, Health Net rise
AP - Wed Mar 23, 3:55PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq stock market:
POM: 26.93 (+5.69), GILD: 80.54 (-2.83), NKE: 52.70 (-1.42), CERU: 2.05 (-0.09), FRED: 15.21 (-0.37), RHT: 73.80 (-4.59), NEM: 37.30 (+1.91), HNT: 67.19 (+2.38)
Top Penny Stocks On Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 12:24PM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. BBLU, LUNA, CERU, and SFOR have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
LUNA: 1.20 (unch), CERU: 2.05 (-0.09), BBLU: 0.04 (-0.01)
Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue
BusinessWire - Wed Mar 23, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of clinical data for its lead compound, CRLX101, in the journal Proceedings of the National Academy of Sciences (PNAS). The publication highlights results from an investigator-sponsored clinical trial, in which pre- and post- treatment tumor biopsies from patients with gastric cancer treated with CRLX101 show the presence of CRLX101 and its payload, camptothecin, in tumors, and their absence in surrounding normal tissue. Importantly, inhibition of the molecular targets of CRLX101 was demonstrated in post-treatment biopsies. The article was published online. Initial results from the trial were presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on November 7, 2015.
CERU: 2.05 (-0.09)
Cerulean Presents CRLX301 Phase 1 Data at the 14th International Congress on Targeted Anticancer Therapies
BusinessWire - Mon Mar 21, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of data from the Company's ongoing Phase 1/2a study of CRLX301 in patients with refractory solid tumors. CRLX301 is an NDC designed to concentrate in tumors and slowly release its payload, docetaxel, inside the cancer cells while sparing healthy tissue. The abstract, entitled "A phase 1 study of CRLX301, a novel Nanoparticle-Drug Conjugate (NDC) containing docetaxel, in patients with refractory solid tumors," will be presented during a poster session at the 14th International Congress on Targeted Anticancer Therapies being held March 21-23, 2016, in Washington, DC.
CERU: 2.05 (-0.09)
Cerulean Announces Data Presentations at the 2016 American Association for Cancer Research Annual Meeting
BusinessWire - Wed Mar 16, 3:37PM CDT
--Four Poster Presentations Featuring Preclinical and Clinical Data for CRLX101 and CRLX301
CERU: 2.05 (-0.09)
